BCT adds Halaven to its list
 

BCT (breastcancertrials.org) just added Halaven and Prolia to its list:

"We added Halaven®/Eribulin (Chemotherapy) and Prolia®/Denosumab (Biological Therapy for Bone Mets), two newly approved drugs, to our treatment section.

· On the Metastatic Health History form, we added four new options to "sites with current evidence of disease": breast, chest wall, skin, and ovaries, in order to match to trials more accurately.

· We added a feature whereby studies that do not require visits to a research site are placed at the top of your "My Trials" list. Eligible participants can live anywhere in the United States and participate from home.

Please continue to Contact Us with your comments and suggestions. Your feedback helps us improve our service.


Sincerely,
The BCT Team"